Sunshine Biopharma Inc. - Company Overview

Core Business Activities

• Industry: Pharmaceutical and biotechnology company
• Focus Areas: Development and commercialization of medicines in oncology (cancer treatment) and antivirals (viral infections)
• Subsidiaries:
  • Nora Pharma Inc. (Canada):
    • Sells 70 generic prescription drugs in Canada
    • Operates a licensed warehouse and administrative facility in Varennes, Quebec (23,500 sq ft, lease until 2030)
    • Holds 200 DINs (Drug Identification Numbers) for prescription drugs
    • Owns 4 NPNs (Natural Product Numbers) for OTC products (e.g., Essential•9™, Calcium-Vitamin D, L-Citrulline, Taurine)
    • Has distribution agreements for 10 additional generic drugs
    • In-market products and an active pipeline of 64 drugs (including 13 expected launches in 2025)
  • Sunshine Biopharma Canada Inc.: Develops and sells OTC supplements

Proprietary Drug Development Programs

• K1.1 mRNA:
  • Target: Liver cancer (Hepatocellular carcinoma)
  • Status: In animal testing, showing promise in reducing tumor size in xenograft mouse models
  • Patent: Filed a provisional patent application (April 2022)
  • Approach: Uses lipid nanoparticle (LNP) technology similar to COVID-19 vaccines, bearing anti-cancer properties
• SBFM-PL4:
  • Target: SARS Coronavirus (COVID-19) virus
  • Focus: Developing small-molecule protease (PLpro) inhibitors
  • Collaborations: Licensed technology from the University of Arizona, with studies showing antiviral activity and favorable pharmacokinetics in animals
  • Publication: Research published in Journal of Medicinal Chemistry (August 2024)

Business Operations and Revenue

• Commercial Sales:
  • Products sold in Canada, primarily through Nora Pharma’s sales team
  • Sales channels: Retail pharmacies, distributors, wholesale agreements
  • Market positioning: Competes in a Canadian market worth $9.7 billion USD in 2023, expected to grow at a CAGR of 7.9%
• Revenue for FY 2024:
  • $34.9 million USD (up from $24.1 million USD in 2023)
• Expenses:
  • Cost of goods sold (2024): $24.2 million USD
  • General & Administrative (2024): $16.5 million USD
• Net Loss (2024):
  • $5.1 million USD (compared to $4.5 million USD in 2023)
• Employees:
  • Total employees as of the report: 52 employees

Financial Highlights

• Cash and Cash Equivalents (as of Dec 31, 2024):
  • $9.7 million USD
• Funding & Capital:
  • Raised approx. $3.6 million USD via warrant exercises in 2024
  • Completed a private placement raising $4.1 million USD in May 2023
  • Conducted a public offering in February 2024, raising $8.5 million USD
  • Issued and exercised warrants and preferred stock to fund operations and acquisitions
• Outstanding Shares (as of April 1, 2025):
  • 2,707,541 shares of common stock (down from 14,012 shares before reverse splits)
• Stockholders:
  • The Chief Executive Officer owns 130,000 Series B Preferred Shares (each voting as 1,000 votes per share), and small holdings in common stock and warrants

Regulatory and Market Focus

• Operating in a heavily regulated environment (FDA, Health Canada)
• Two main revenue streams: generic drugs in Canada and proprietary medicinal products in development
• Competes with large pharmaceutical companies (Pfizer, Merck, Gilead, etc.) and smaller biotech firms
• Future focus: commercialization of new drugs following regulatory approvals, expand product pipeline, and licensing agreements

Summary

Sunshine Biopharma Inc. is a pharmaceutical company engaged in the sale of approximately 70 generic prescription drugs in Canada through its wholly owned subsidiary Nora Pharma, with a pipeline of additional drugs aimed at expanding its market share in a $9.7 billion USD Canadian generics market. It is also developing proprietary drug candidates targeting liver cancer and COVID-19 via advanced mRNA and small molecule technologies. The company has reported revenue of $34.9 million USD in 2024 and a net loss of $5.1 million USD, with 52 employees as of the report date. Its financial strategy involves raising capital through warrants, stock issuance, and licensing agreements, while focusing on regulatory approvals and product launches.